Received May 20, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | 027A21A | IM |
immunocompromised; This spontaneous case was reported by a consumer and describes the occurrence of IMMUNODEFICIENCY (immunocompromised) in a 7-decade-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027A21A) for COVID-19 prophylaxis. No Medical History information was reported. On 08-Mar-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) 1 dosage form. On an unknown date, the patient experienced IMMUNODEFICIENCY (immunocompromised) (seriousness criterion medically significant). The patient was treated with Transplant (stem cell transplant) for Immunodeficiency. At the time of the report, IMMUNODEFICIENCY (immunocompromised) had not resolved. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) was unknown. Concomitant medication was not reported. It was stated that patient had a Moderna COVID vaccine on 08-Mar-2021 and had stem cell transplant on 11-Mar-2026, added that wiped out his immune system and so he had no immunity right now. He was just starting to get his vaccines and one of the first ones they asked him to get was a Covid-19 and was just wondering what the minimum interval time between COVID-19 vaccines was for somebody who was over 65 and immunocompromised. It was clarified that he received mNEXSPIKE as well as Shingrix on 12-May-2026. He thought what he was just finding out was there a little discrepancy between his clinical healthcare provider being his hematologist-oncologist and the pharmacy community at the pharmacies where he got these vaccines. No additional details provided. It was unknown if the patient experienced any additional symptoms/events.; Reporter's Comments: Company Comment: The event was assessed as not related due to long latency. The benefit-risk relationship of the product is not affected by this report.